Category

• Business2

Organizations

• Bausch + Lomb64
• Alcon, Inc.43
• Eyes On Eyecare43
• American Optometric Association34
• Harrow28
• Glaukos26
• Regeneron22
• Topcon Healthcare22
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• AMD2
• DME2
• Acquisitions2
• Retina2
• Clinical Trials1
• Wet Amd1

• Organizations: Merck✕

Clear all

Business

Merck officially enters ophthalmic space with EyeBio acquisition

Pharmaceutical giant now owns Restoret (EYE103), an investigational, tri-specific antibody for DME and wet AMD.

Business

Merck to acquire Eyebiotech in deal worth up to $3B

Agreement involves EyeBio’s lead retinal vascular disease candidate, Restoret, designed as an intravitreal injection for DME and wet AMD patients.